WUXI BIOLOGICS (CAYM

2269

Delayed - 05/20 04:08:13 am
56.3HKD	+7.85%

Healthcare
	Pharmaceuticals & Medical Research
		Pharmaceuticals
			Pharmaceuticals
				Biopharmaceuticals

WUXI BIOLOGICS (CAYMAN) INC. is an investment holding company. The Company along with its subsidiaries is mainly engaged in the discovery, research and development, manufacturing and sales of biologics products. The Companyâ€™s primary products include the clinical active pharmaceutical ingredients, sterile liquid preparations, freeze-dried preparations, as well as small molecules antibiotics for injection drugs. The Company mainly distributes its products in the United States of America (USA) and the Peopleâ€™s Republic of China (PRC) markets.

Number of employees : 9 864 people.

	2020		2021
Research Services on Fee-for-Service	6 022.80	95.5%	9 684.28	78.1%
Commercial Manufacturing Contracts	37.67	0.6%	1 987.74	16%
Other Biologics Products	95.78	1.5%	418.12	3.4%
Research Services on Full-Time-Equivalent	148.05	2.3%	289.87	2.3%
Project Management Organization Services	2.30	0%	21.66	0.2%
HKD in Million

	2020		2021
North America	2 785.81	44.2%	6 301.89	50.8%
China	2 768.91	43.9%	3 025.97	24.4%
Europe	501.85	8%	2 743.38	22.1%
Rest of the World	250.03	4%	330.45	2.7%
HKD in Million

Name	Title
Zhi Sheng Chen	Director
Ming Tu	Chief Financial Officer & Executive Vice President
Ge Li	Non-Executive Chairman
Weichang Zhou	Chief Technology Officer & Executive Director
William Robert Keller	Independent Non-Executive Director
Teh Ming Kwauk	Independent Non-Executive Director
Kenneth Walton Hitchner	Independent Non-Executive Director
Ning Zhao	Non-Executive Director
Yan Ling Cao	Non-Executive Director
Yi Bing Wu	Non-Executive Director

Name	Equities	%
Wuxi Biologics Holdings Ltd.	650,251,133	15.4%
Capital Research & Management Co. (World Investors)	287,262,037	6.81%
The Vanguard Group, Inc.	101,702,322	2.41%
BlackRock Fund Advisors	96,653,000	2.29%
JPMorgan Investment Management, Inc.	95,131,500	2.26%
Capital Research & Management Co. (Global Investors)	69,291,216	1.64%
JPMorgan Asset Management (Asia Pacific) Ltd.	61,145,500	1.45%
WCM Investment Management LLC	46,526,147	1.10%
Fidelity Management & Research Co. LLC	45,348,195	1.08%
Norges Bank Investment Management	43,899,484	1.04%

Name	Equities	%
Franklin Advisers, Inc.	975,235	0.046%
Parametric Portfolio Associates LLC	635,605	0.030%
Thomas White International Ltd.	167,063	0.0079%
Equitable Trust Co.	149,389	0.0071%
CapFinancial Partners LLC	24,999	0.0012%
Envestnet Asset Management, Inc.	24,396	0.0012%
MAI Capital Management LLC	22,962	0.0011%
Confluence Investment Management LLC	20,136	0.0010%
Fisher Asset Management LLC	18,622	0.0009%
Boston Private Wealth LLC	15,372	0.0007%

Wuxi Biologics (Cayman), Inc.
No. 108, Meiliang Road
Mashan
Wuxi, Jiangsu 214092

Phone : +86.510.81831205
Web : http://www.wuxibiologics.com

	1st jan.	Capi. (M$)

WUXI BIOLOGICS (CAYMAN) INC.	-40.07%	28 063



CSL LIMITED	-5.75%	93 171
SAMSUNG BIOLOGICS CO.,LTD.	-10.52%	44 721
BIOGEN INC.	-16.78%	28 278
WUXI BIOLOGICS (CAYMAN) INC.	-43.60%	28 063
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-25.71%	21 889
UCB	-13.28%	17 758
BIOMARIN PHARMACEUTICAL INC.	-9.77%	14 666
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.	0.34%	13 487
GRIFOLS, S.A.	17.81%	12 265
WALVAX BIOTECHNOLOGY CO., LTD.	-15.43%	11 234
BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED	-11.66%	8 952
SK BIOSCIENCE CO.,LTD.	-43.56%	7 364
CELLTRION HEALTHCARE CO., LTD.	-28.43%	6 649
SWEDISH ORPHAN BIOVITRUM AB (PUBL)	14.69%	6 320
SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.	-37.84%	6 125
APELLIS PHARMACEUTICALS, INC.	-5.22%	4 738
HUALAN BIOLOGICAL ENGINEERING INC.	-40.84%	4 496
BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.	-23.03%	4 272
INNOVENT BIOLOGICS, INC.	-55.23%	4 036
CANSINO BIOLOGICS INC.	-60.57%	3 701

» More brands of WuXi Biologics (Cayman) Inc.